» Articles » PMID: 26385972

A Review of X-linked Charcot-Marie-Tooth Disease

Overview
Journal J Child Neurol
Specialties Neurology
Pediatrics
Date 2015 Sep 20
PMID 26385972
Citations 28
Authors
Affiliations
Soon will be listed here.
Abstract

X-linked Charcot-Marie-Tooth disease (CMTX) is the second common genetic variant of CMT. CMTX type 1 causes 90% of CMTX. The most important clinical features of CMTX are similar with other types of CMT; however, a few patients get the central nervous system involved with or without white matter lesions; males are more severely and earlier affected than females. In this review, the authors focus on the origin and classification of CMTX, the central nervous system manifestations of CMTX1, the possible mechanism by which GJB1 mutations cause CMT1X, and the emerging therapeutic strategies for CMTX. Moreover, several cases are presented to illustrate the central nervous system manifestations.

Citing Articles

Current Treatment Methods for Charcot-Marie-Tooth Diseases.

Dong H, Qin B, Zhang H, Lei L, Wu S Biomolecules. 2024; 14(9).

PMID: 39334903 PMC: 11430469. DOI: 10.3390/biom14091138.


Hereditary spastic paraplegia and extensive leukoencephalopathy: a case report of a unique phenotype associated with a GJB1/Cx32 p.Pro174Ser variant.

Nakamura H, Doi H, Miyaji Y, Wada T, Takahashi E, Tada M BMC Neurol. 2024; 24(1):310.

PMID: 39232641 PMC: 11373513. DOI: 10.1186/s12883-024-03823-9.


Episodic Neurological Dysfunction in X-Linked Charcot-Marie-Tooth Disease: Expansion of the Phenotypic and Genetic Spectrum.

Zhan F, Tian W, Cao Y, Wu J, Ni R, Liu T J Clin Neurol. 2024; 20(1):59-66.

PMID: 38179633 PMC: 10782082. DOI: 10.3988/jcn.2023.0104.


Clinical and Genetic Aspects of Childhood-Onset Demyelinating Charcot-Marie-Tooth's Disease in Brazil.

Machado R, Souza P, Farias I, Badia B, Filho J, Lima R J Pediatr Genet. 2024; 12(4):301-307.

PMID: 38162165 PMC: 10756728. DOI: 10.1055/s-0042-1747934.


Gene replacement therapy in two Golgi-retained CMT1X mutants before and after the onset of demyelinating neuropathy.

Kagiava A, Karaiskos C, Lapathitis G, Heslegrave A, Sargiannidou I, Zetterberg H Mol Ther Methods Clin Dev. 2023; 30:377-393.

PMID: 37645436 PMC: 10460951. DOI: 10.1016/j.omtm.2023.07.011.